In a filing, CRISPR Therapeutics AG revealed its Chief Medical Officer Patel Naimish unloaded Company’s shares for reported $0.14 million on May 29 ’25. In the deal valued at $35.94 per share,3,932 shares were sold. As a result of this transaction, Patel Naimish now holds 6,068 shares worth roughly $0.27 million.
Then, Kulkarni Samarth sold 10,031 shares, generating $413,578 in total proceeds. Upon selling the shares at $41.23, the Chief Executive Officer now owns 195,085 shares.
Before that, Bruno Julianne sold 1,714 shares. CRISPR Therapeutics AG shares valued at $70,668 were divested by the Chief Operating Officer at a price of $41.23 per share. As a result of the transaction, Bruno Julianne now holds 10,544 shares, worth roughly $0.47 million.
Evercore ISI upgraded its CRISPR Therapeutics AG [CRSP] rating to an Outperform from a an In-line in a research note published on February 14, 2025; the price target was increased to $99 from $60. A number of analysts have revised their coverage, including TD Cowen’s analysts, who increased its forecast for the stock in mid February from “a Sell” to “a Hold”. H.C. Wainwright began covering CRSP with “Buy” recommendation on February 03, 2025. Needham maintained its rating on August 06, 2024. It rated CRSP as “a Buy”.
Price Performance Review of CRSP
On Friday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock jump 4.85% to $44.13. Over the last five days, the stock has gained 16.01%. CRISPR Therapeutics AG shares have risen nearly 12.12% since the year began. Nevertheless, the stocks have fallen -26.40% over the past one year.
Levels Of Support And Resistance For CRSP Stock
The most recent change occurred on August 02, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $90 price target.
